New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

Corporate Breaking News

Home : New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

May 13 2021	New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
THOUSAND OAKS, Calif., May 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secondary...


Source:https://www.prnewswire.com:443/news-releases/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients-301290490.html

Related News
» Inefficient contracting remains major challenge for businesses, EY/Harvard Law School Center on the Legal Profession survey finds » Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer's Disease 7 Years Before Symptoms Occur